Merck Net Worth 2010-2024 | MRK

Interactive chart of historical net worth (market cap) for Merck (MRK) over the last 10 years. How much a company is worth is typically represented by its market capitalization, or the current stock price multiplied by the number of shares outstanding. Merck net worth as of January 31, 2025 is $248.61B.
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $248.613B $60.115B
Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda, Simponi , Januvia and Janumet, Bridion, Isentress, ProQuad, Gardasil, Pneumovax 23, RotaTeq and Belsomra. Merck made its biggest acquisition of Schering-Plough and sold off its Consumer Care business to Bayer. Other key acquisitions include Idenix Pharmaceuticals, Cubist Pharmaceuticals, Rigontec, ArQule and Acceleron Pharma. IMerck spun off products from its Women's Health unit, legacy drugs and biosimilar products into a new publicly traded company called Organon & Co.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $763.326B 79.06
Novo Nordisk (NVO) Denmark $377.087B 27.19
Johnson & Johnson (JNJ) United States $363.912B 15.13
AbbVie (ABBV) United States $309.709B 16.30
Roche Holding AG (RHHBY) Switzerland $247.847B 0.00
AstraZeneca (AZN) United Kingdom $217.852B 18.54
Novartis AG (NVS) Switzerland $210.389B 13.98
Pfizer (PFE) United States $150.855B 10.32
Sanofi (SNY) $132.349B 11.99
Bayer (BAYRY) Germany $22.242B 3.56
Innoviva (INVA) United States $1.183B 9.84